Literature DB >> 22771252

Alternative diets to the classical ketogenic diet--can we be more liberal?

Maria J Miranda1, Zahava Turner, Gwyneth Magrath.   

Abstract

The ketogenic diet (KD), a high-fat, adequate protein, low-carbohydrate diet has been used since 1921 for the treatment of severe medically refractory epilepsy. In the past 15 years, the use of the KD has expanded enormously and a huge amount of clinical evidence of its efficacy is available. The classical KD is however restrictive and therefore alternative more liberal varieties of the classical KD have been developed within the last 8 years. The purpose of this report is to summarise the principles and evidence of effectiveness of the alternative ketogenic diets: Medium Chain Triglyceride (MCT)-KD, modified Atkins diet (MAD) and low glycaemic index treatment (LGIT), compared to the classical KD. The clinical evidence to date suggests that the more liberal versions of the classical KD such as MCT KD, MAD and LGIT have an efficacy close to the classical KD; however, no RCT data are available for MAD and LGIT. This evidence suggests that factors such as age, epilepsy type, lifestyle and resources are important factors in deciding which diet we should start a patient on. This report intends to summarise guidelines based on the evidence available.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22771252     DOI: 10.1016/j.eplepsyres.2012.06.007

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  13 in total

1.  Dietary Treatments for Epilepsy: Why Is This So Hard for Us to Swallow?

Authors:  Adriana Bermeo-Ovalle
Journal:  Epilepsy Curr       Date:  2016 Sep-Oct       Impact factor: 7.500

2.  Dietary therapies for epilepsy and other neurological disorders: highlights of the 3rd international symposium.

Authors:  Carl E Stafstrom
Journal:  Epilepsy Curr       Date:  2013-03       Impact factor: 7.500

Review 3.  Refractory epilepsy in children.

Authors:  Satinder Aneja; Puneet Jain
Journal:  Indian J Pediatr       Date:  2014-08-09       Impact factor: 1.967

4.  The Efficacy of Ketogenic Therapies in the Clinical Management of People with Neurodegenerative Disease: A Systematic Review.

Authors:  Lauren S Dewsbury; Chai K Lim; Genevieve Z Steiner
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

Review 5.  Lower fat and better quality diet therapy for children with pharmacoresistant epilepsy.

Authors:  Jung-Rim Yoon; Heung Dong Kim; Hoon-Chul Kang
Journal:  Korean J Pediatr       Date:  2013-08-27

6.  Childhood absence epilepsy successfully treated with the paleolithic ketogenic diet.

Authors:  Zsófia Clemens; Anna Kelemen; András Fogarasi; Csaba Tóth
Journal:  Neurol Ther       Date:  2013-09-21

7.  Monitoring for compliance with a ketogenic diet: what is the best time of day to test for urinary ketosis?

Authors:  Paul Urbain; Hartmut Bertz
Journal:  Nutr Metab (Lond)       Date:  2016-11-04       Impact factor: 4.169

8.  Non-ketogenic combination of nutritional strategies provides robust protection against seizures.

Authors:  Glenn Dallérac; Julien Moulard; Jean-François Benoist; Stefan Rouach; Stéphane Auvin; Angèle Guilbot; Loïc Lenoir; Nathalie Rouach
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

9.  Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study.

Authors:  Elles J T M van der Louw; Joanne F Olieman; Patricia M L A van den Bemt; Jacoline E C Bromberg; Esther Oomen-de Hoop; Rinze F Neuteboom; Coriene E Catsman-Berrevoets; Arnaud J P E Vincent
Journal:  Ther Adv Med Oncol       Date:  2019-06-21       Impact factor: 8.168

10.  Optimal clinical management of children receiving ketogenic parenteral nutrition: a clinical practice guide.

Authors:  Elles van der Louw; Vanessa Aldaz; Jessica Harvey; Marian Roan; Dorine van den Hurk; J Helen Cross; Stéphane Auvin
Journal:  Dev Med Child Neurol       Date:  2019-07-16       Impact factor: 5.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.